Li D - Search Results

1

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations.

Cale JM, Ham KA, Li D, McIntosh CS, Watts GF, Wilton SD, Aung-Htut MT. Cale JM, et al. Among authors: li d. Sci Rep. 2023 Nov 13;13(1):19725. doi: 10.1038/s41598-023-47005-y. Sci Rep. 2023. PMID: 37957262 Free PMC article.

2

Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.

Li D, Mastaglia FL, Fletcher S, Wilton SD. Li D, et al. Trends Pharmacol Sci. 2018 Nov;39(11):982-994. doi: 10.1016/j.tips.2018.09.001. Epub 2018 Sep 30. Trends Pharmacol Sci. 2018. PMID: 30282590 Review.

3

Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era.

Li D, Mastaglia FL, Fletcher S, Wilton SD. Li D, et al. Med Res Rev. 2020 Nov;40(6):2650-2681. doi: 10.1002/med.21718. Epub 2020 Aug 6. Med Res Rev. 2020. PMID: 32767426 Free PMC article. Review.

4

A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson's Disease Arising from Parkin Mutations.

Li D, Aung-Htut MT, Ham KA, Fletcher S, Wilton SD. Li D, et al. Int J Mol Sci. 2020 Oct 1;21(19):7282. doi: 10.3390/ijms21197282. Int J Mol Sci. 2020. PMID: 33019779 Free PMC article.

5

Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein.

Li D, Adams AM, Johnsen RD, Fletcher S, Wilton SD. Li D, et al. Mol Ther Nucleic Acids. 2020 Aug 21;22:263-272. doi: 10.1016/j.omtn.2020.08.019. eCollection 2020 Dec 4. Mol Ther Nucleic Acids. 2020. PMID: 33230432 Free PMC article.

6

Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.

Li D, McIntosh CS, Mastaglia FL, Wilton SD, Aung-Htut MT. Li D, et al. Transl Neurodegener. 2021 May 20;10(1):16. doi: 10.1186/s40035-021-00240-7. Transl Neurodegener. 2021. PMID: 34016162 Free PMC article. Review.

7

Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.

Li D, McIntosh CS, Mastaglia FL, Wilton SD, Aung-Htut MT. Li D, et al. Transl Neurodegener. 2021 Oct 25;10(1):41. doi: 10.1186/s40035-021-00267-w. Transl Neurodegener. 2021. PMID: 34696812 Free PMC article. No abstract available.

8

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies.

McIntosh CS, Li D, Wilton SD, Aung-Htut MT. McIntosh CS, et al. Among authors: li d. Biomedicines. 2021 Oct 20;9(11):1499. doi: 10.3390/biomedicines9111499. Biomedicines. 2021. PMID: 34829728 Free PMC article. Review.

9

Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

Li D, Mastaglia FL, Yau WY, Chen S, Wilton SD, Akkari PA. Li D, et al. Mov Disord. 2022 Nov;37(11):2184-2190. doi: 10.1002/mds.29201. Epub 2022 Aug 29. Mov Disord. 2022. PMID: 36036206 Free PMC article. No abstract available.

10

Antisense oligonucleotides and their applications in rare neurological diseases.

McDowall S, Aung-Htut M, Wilton S, Li D. McDowall S, et al. Among authors: li d. Front Neurosci. 2024 Sep 23;18:1414658. doi: 10.3389/fnins.2024.1414658. eCollection 2024. Front Neurosci. 2024. PMID: 39376536 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52,857 results

Search Page

Filters